	Name of the Issuer:	Jupiter Life Line Hospitals Limited	Last updated on	31-May-24	
1	Type of Issue (IPO / FPO)	IPO			
	Source: Prospectus dated September 11, 2023				
2	Issue Size (Rs. Million)*#	8,690.76			
	- Fresh Issue Size (Rs. Millions)	5,420.01			
	- Offer for Sale Component (Rs. Millions)	3,270.75			
	# The Company has, in consultation with the BRLMs	, undertaken a private placement of 1,673,469	Equity Shares aggregating to ₹ 1,229.99 mil	llion ("Pre-IPO Placement"). The s	ize of the Fresh Issue of Equity Shares has
	been adjusted to ₹1,229,99 million		, ,	,	, ,

3 Grade of issue along with name of the rating agency

*Source: Prospectus dated September 11, 2023

Name Not Applicable Not Applicable

Source: Prospectus dated September 11, 2023

4 Subscription Level (Number of times)

65.44*

*The above figure is after technical rejections, multiple or duplicate Bids and Bids not banked/returned.

5 QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges

Particulars	%
(i) allotment in the issue**	13.50%
(ii) at the end of 1st Quarter immediately after the listing (September 30, 2023)^	20.76%
(iii) at the end of 1st FY (March 31, 2024)^	21.75%
(iv) at the end of 2nd FY (March 31, 2025)*	Not Available
(v) at the end of 3rd FY (March 31, 2026)*	Not Available

^{**}As a % of total paid up capital as per prospectus dated September 11, 2023

6 Financials of the issuer

			(In Rs. Millions)
Parameters	1st FY (March 31, 2024)	2nd FY (March 31, 2025)*	3rd FY (March 31, 2026)*
Income from Operations	10,695.00	Not Available	Not Available
Net Profit for the period	1,766.12	Not Available	Not Available
Paid-up equity share capital	655.66	Not Available	Not Available
Reserves excluding revaluation reserves	11,031.73	Not Available	Not Available

^{*}Financials not disclosed as reporting for the relevant fiscal year has not been completed.

Trading Status in the scrip of the issuer

Company's Equity Shares are listed on both BSE Limited and National Stock Exchange of India Limited The Shares have not been suspended or delisted.

Particulars	Status
(i) at the end of 1st FY (March 31, 2024)	Frequently traded
(ii) at the end of 2nd FY (March 31, 2025)*	Not Available
(iii) at the end of 3rd FY (March 31, 2026)*	Not Available

^{*}Trading status not disclosed as the relevant fiscal year has not been completed. Source: Stock exchange data.

8 Change in Directors of issuer from the disclosures in the offer document

Particulars	Name of the Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2024)*	-	-
(ii) at the end of 2nd FY (March 31, 2025)*#	Not Available	Not Available
(iii) at the end of 3rd FY (March 31, 2026)*	Not Available	Not Available

⁽iii) at the end of 3rd FY (March 31, 2026)* Not Available

* Changes in Directors not disclosed as the relevant fiscal year has not been completed.

Updated till May 31, 2024

^{*}Source: Final post issue report dated September 11, 2023

[^]Holding of institutions category as disclosed to Stock Exchanges

^{*}QIB Holding not disclosed as reporting for the relevant period / fiscal year has not been completed.

9 Status of implementation of project/ commencement of commercial production

(i) as disclosed in the offer document	Not applicable*
(ii) Actual implementation	Not applicable*
(iii) Reasons for delay in implementation, if any	Not applicable*
*The Company did not undertake any project	

10 Status of utilization of issue proceeds

(i) As disclosed in the offer document

Estimated Utilisation of Net Proceeds and the Pre-IPO Placement

Particular	Amount to be funded from the Net Proceeds	Fiscal 2024	Fiscal 2025	Fiscal 2026
Repayment/pre-payment, in full or part, of borrowings availed from banks by the Company and Material Subsidiary	5,101.55	5,101.55	-	-
General Corporate Purpose	11.63	11.63	-	
Total (1)	5,113.18	5,113.18		
Sourced from Prospectus dated September 11, 2023				

(ii) Actual utilization

Actual Utilisation of Net Proceeds and the Pre-IPO Placement

Actual Chilisation of Net Proc	eeds and the Fre-IFO	riacement
Fiscal 2024*#	Fiscal 2025*	Fiscal 2026*
5,101.55	Not Available	Not Available
11.63	Not Available	Not Available
year has not been completed.		
rahle		
	Fiscal 2024* [#] 5,101.55 11.63	5,101.55 Not Available 11.63 Not Available year has not been completed.

11 Comments of monitoring agency (a) Comments on use of funds

Not Applicable*

(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the

No Deviation*

offer document

(c) Any other reservations expressed by the monitoring agency about the end use of funds *Report issued by Monitoring agent dated May 10, 2024

12 Pricing Data
Issue Price (Rs.):
Designated Stock Exchange:
Listing Date: 735 NSE 18-Sep-23

Price parameters	At close of listing day	At close of 30th calendar day from	•	As at the	As at the end of 1st FY after the listing of the issue (March 31, 2024) ⁽³⁾⁽⁴⁾	
	(September 18, 2023)	listing day (October 17, 2023) ⁽¹⁾	listing day (December 16, 2023) ⁽²⁾	Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange ⁽⁵⁾	1,075.75	1045.65	1,150.60	1,192.70	1,653.95	970.00
NIFTY 50 ⁽⁵⁾	20,133.30	19811.50	21,456.65	22,462.00	22,526.60	17,312.75
Sectoral Index ⁽⁶⁾	N	Not Applicable		Not Applicable		

Price parameters	As at the end of 2nd FY after the listing of the issue (March 31, 2025) ⁽³⁾⁽⁴⁾		As at the end of 3rd FY after the listing of the issue (March 31, 2026) ^{(3) (4)}			
	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange ⁽⁵⁾	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
NIFTY 50 ⁽⁵⁾	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
Sectoral Index ⁽⁶⁾	Not Applicable			Not Applicable		

Source: NSE website

- (1) 30th calendar day shall be taken as listing date plus 29 calendar days. (2) 90th calendar day shall be taken as listing date plus 89 calendar days.

- (3) High and Low based on intra day prices
 (4) Pricing data not disclosed as the relevant period/ fiscal year has not completed
- (5) In case of any reporting day falling on a holiday, next trading day prices/values have been disclosed.
- (6) Comparable Sectoral index is not available

13 Basis for Issue Price

Accounting ratio		As disclosed in the	At the end of 1st FY	At the end of 2nd FY	At the end of 3rd FY
		offer document (1)	(March 31, 2024)	(March 31, 2025) ⁽²⁾	(March 31, 2026) (2)
EPS (Basic)	Issuer:				
	Consolidated (Basic)	13.95	28.65	Not Available	Not Available
	Consolidated (Diluted)	12.95	28.65	Not Available	Not Available
	Peer Group: (Diluted)				
	Apollo Hospitals Enterprise Limited	Basic - 56.97	Basic - 70.28	Not Available	Not Available
		Diluted - 56.97	Diluted - 70.28		
	Fortis Healthcare Limited	Basic - 7.80	Basic -2.64	Not Available	Not Available
		Diluted - 7.80	Diluted - 2.64		
	Max Healthcare Institute Limited	Basic - 11.38	Basic - 7.07	Not Available	Not Available
		Diluted - 11.36	Diluted - 7.05		
	Narayana Hrudayalaya Limited	Basic - 29.85	Basic -20.90	Not Available	Not Available
		Diluted - 29.85	Diluted - 20.90		
	Global Health Limited	Basic - 12.58	Basic -17.80	Not Available	Not Available
		Diluted - 12.57	Diluted - 17.80		
	Krishna Institute of Medical	Basic - 42.03	Basic -29.41	Not Available	Not Available
	Sciences Limited	Diluted - 42.03	Diluted - 29.41		
	Industry Avg:	N.A	N.A.	N.A.	N.A
Price to Earnings Ratio (P/E)	Issuer:	50.70	44.00		
	Consolidated (Basic)	56.76	41.63	Not Available	Not Available
	Consolidated (Diluted)	56.76	41.63	Not Available	Not Available
	Peer Group (Consolidated)				
	Apollo Hospitals Enterprise Limited	Basic - 84.64	Basic - 91.82	Not Available	Not Available
		Diluted - 84.64	Diluted - 91.82		
	Fortis Healthcare Limited	Basic - 40.26	Basic -162.25	Not Available	Not Available
		Diluted - 40.26	Diluted - 162.25		
	Max Healthcare Institute Limited	Basic - 45.97	Basic -115.21	Not Available	Not Available
		Diluted - 45.97	Diluted -115.54		
	Narayana Hrudayalaya Limited	Basic - 33.14	Basic - 61.89	Not Available	Not Available
		Diluted - 33.14	Diluted - 61.89		
	Global Health Limited	Basic - 53.70 Diluted - 53.70	Basic - 74.69 Diluted - 74.69	Not Available	Not Available
	Krishna Institute of Medical Sciences Limited	Basic - 45.09 Diluted - 45.09	Basic - 69.54 Diluted - 69.54	Not Available	Not Available
	Industry Avg:	50.47	N.A.	N.A.	N.A
20NIM/(0/)	Industry Avg:	50.47	N.A.	N.A.	N.A
RoNW(%)	Consolidated	20.03%	15.11%	Not Available	Not Available
		20.03%	15.11%	Not Available	NOT AVAIIABLE
	Peer Group: (Consolidated) Apollo Hospitals Enterprise Limited	16.40%	40.400/	Not Available	Ni-a Ail-li-l
	Fortis Healthcare Limited	20.90%	13.10%		Not Available
	Max Healthcare Institute Limited		2.19%	Not Available	Not Available Not Available
		62.80%	8.95%	Not Available	Not Available Not Available
	Narayana Hrudayalaya Limited Global Health Limited	35.40%	27.36%	Not Available	Not Available Not Available
		16.20%	16.45%	Not Available	
	Krishna Institute of Medical	25.70%	12.61%	Not Available	Not Available
	Sciences Limited				
	Industry Avg:	N.A	N.A	N.A	N.A

Issuer:				
Consolidated	64.39	178.25	Not Available	Not Available
Peer Group: (Consolidated)				
Apollo Hospitals Enterprise Limited	378.33	536.28	Not Available	Not Available
Fortis Healthcare Limited	46.67	120.37	Not Available	Not Available
Max Healthcare Institute Limited	24.14	79.03	Not Available	Not Available
Narayana Hrudayalaya Limited	90.5	90.05	Not Available	Not Available
Global Health Limited	90.35	108.21	Not Available	Not Available
Krishna Institute of Medical Sciences Limited	193.96	233.23	Not Available	Not Available
Industry Ava:	NΛ	NΛ	NΛ	NΑ

- (1) Prospectus dated September 11, 2023
- (2) Information not provided as the relevant fiscal year has not completed

Source:

- * All the financial information for the Company above is sourced from the Restated Summary Stati ment
- **Information for the industry peers mentioned above is on a consolidated basis and is sourced/de rived from the respective annual results for the year ended March 31, 2023 of s ch industry peers available on the website of stock exchange

Notes:

- 1) Earnings per share (Basic) = Restated net profit afte r tax, available for equity shareholders/Weghted average number c f equity shares outstar ding during the period/year.
- 2) Earnings per share (Diluted) = Restated profit for the period/year / Weighted average number cf diluted potential equity shares
- 3) Return on Net Worth (For Jupiter Life Line Hospitals Limited) (%) = Restated net profit after tax / Restated Net Worth at the end of the
- 4) Return on Net Worth (For listed industry peers) (%) = Profit after tax / Tangible Net Worth.
- 5) Net Worth means the aggregate value of the paid-up share capital and all reserves created ou of the profits, securities premium account and debit or credit balance of profit and loss account, after deducting the aggregate value of the accumulated loss s, deferred expenditure and miscellaneou s expenditure not writter off, as per the audited balance sheet, but does not include reserves created
- out 6) Tangible net worth = Total Net Worth – Intangible as: ets.
- 7) Net asset value per share (For Jupiter Life Line Hosp itals Limited) (in ₹) = Restated Net Worth at the end of the period/y ar / Number
- 8) Net asset value per share (For listed industry peers) = Tangible Net Worth as at end of the peri od/year / Number of equity shares
- 9) Operating income = Gross sales + Other related income.
- 10) P/E is calculated basis closing market price of equi ty shares from NSE divided by diluted by the diluted earnings per st are.

14 Any other material information

Date of disclosure	Announcement				
	Trading Members of the Exchange are hereby informed that effective from September 18, 2023, the equity shares of Jupiter Life Line Hospitals Lt.				
18-Sep-23	(Scrip Code: 543980) are listed and admitted to dealings on the Exchange in the list of "B" Group Securities. For further details please refer to the				
	notice no 20230915- dated September 15, 2023.				
20-Sep-23	The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for				
	SBI Mutual Funds				
29-Sep-23	Closure of Trading Window				
30-Sep-23	Board Meeting Intimation for Notice Of Board Meeting To Be Held On Friday October 6, 2023 to Consider And Approve The Unaudited Financial				
	Results Along With Limited Review Report Of The Company For The Quater Ended June 30, 2023 Under Regulation 33 Of The Sebi Listing				
6-Oct-23	Outcome Of The Board Meeting Held On Friday, 6Th October ,2023				
6-Oct-23	Announcement under Regulation 30 (LODR)-Investor Presentation				
6-Oct-23	Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('LODR				
	Regulations') Read With Schedule III Of LODR Regulations And Offer Letter Dated September 11, 2023				
8-Oct-23	Newspaper Publication for Unaudited Financial Results(Standalone and Consolidated) for quarter ended 30th June, 2023				
16-Oct-23	Compliance certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018 for Quater ended 30th September, 2023				
2-Nov-23	Jupiter Life Line Hospitals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2023, inter alia, the scheduled on 10/11/2023 inter alia, the scheduled on 10/				
	consider and approve the Un-audited Financial Results along with the Limited Review Report of the Company for the quarter and half year endec				
	September 30, 2023 under Regulation 33 of the SEBI Listing Regulation				
10-Nov-23	Board Meeting Outcome For The Quater And Half Year Ended September 30, 2023				
10-Nov-23	Investor Presentation for the quarter and half year ended September 30, 2023				
10-Nov-23	Announcement under Regulation 30 (LODR)-Monitoring Agency Report				
10-Nov-23	Statement On Deviation Or Variation Of Funds Under Regulation 32 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 201				
12-Nov-23	Announcement under Regulation 30 (LODR)-Newspaper Publication				
21-Nov-23	Q2 & H1 FY24 Earnings Conference Call- Transcript				
29-Dec-23	INTIMATION OF TRADING WINDOW CLOSURE FOR THE QUATER AND NINE MONTHS ENDED ON 31 DECEMBER, 2023				
29-Dec-23	Jupiter Life Line Hospitals Limited-543980-Closure of Trading Window - XBRL				
11-Jan-24	Pursuant to Reg 74(5) of SEBI (DP) Regulation we are filing the certificate received from RTA for the quarter ended 31st December, 2023				
16-Jan-24	Intimation Under Regulation 30 (5) Of The Securities And Exchange Board Of India ("SEBI") (Listing Obligations And Disclosure Requirements				
18-Jan-24	Intimation Under Regulation 8 Of The Securities And Exchange Board Of India (Prohibition Of Insider Trading) Regulations, 2015.				
1-Feb-24	Board Meeting Intimation for To Consider And Approve The Un-Audited Financial Results Along With The Limited Review Report Of The Company				
1-Feb-24	Jupiter Life Line Hospitals Limited-543980-Closure of Trading Window - XBRL				

9-Feb-24	Board Meeting Outcome for Outcome Of The Board Meeting Held On Friday, February 9, 2024				
9-Feb-24	Outcome Of The Board Meeting Held On Friday, February 9, 2024				
9-Feb-24	Intimation Of Resignation Of Internal Auditor				
9-Feb-24	Intimation Of Appointment Of Internal Auditor				
9-Feb-24	Statement On Deviation Or Variation Of Funds Under Regulation 32 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations,				
9-Feb-24	Announcement under Regulation 30 (LODR)-Investor Presentation				
9-Feb-24	Announcement under Regulation 30 (LODR)-Monitoring Agency Report				
11-Feb-24	Announcement under Regulation 30 (LODR)-Newspaper Publication				
16-Feb-24	Announcement under Regulation 30 (LODR)-Earnings Call Transcript				
22-Feb-24	Jupiter Life Line Hospitals Limited has informed the Exchange regarding 'Intimation under Regulation 30 of SEBI (Listing Obligations and Disclo				
27-Mar-24	Jupiter Life Line Hospitals Limited has informed the Exchange about Credit Rating				
28-Mar-24	Jupiter Life Line Hospitals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider				
28-Mar-24	Jupiter Life Line Hospitals Limited has informed the Exchange about Closure of Trading Window Jupiter Life Line Hospitals Limited has informed the Exchange about Closure of Trading Window				
	Jupiter Life Line Hospitals Limited has informed the Exchange about Critificate under Regulation 74(5) of SEBI (Depositories and Participants)				
6-Apr-24	JUPITER LIFE LINE HOSPITALS LIMITED has informed the Exchange about Board Meeting to be held on 10-May-2024 to inter-alia consider and				
2-May-24	Jupiter Life Line Hospitals Limited has informed the Exchange about Closure of Trading Window				
2-May-24	JUPITER LIFE LINE HOSPITALS LIMITED has informed the Exchange about Board Meeting to be held on 10-May-2024 to consider Dividend.				
7-May-24	Dr. Ankit Ajay Thakker has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of				
10-May-24					
10-May-24	Jupiter Life Line Hospitals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2024.				
10-May-24	Jupiter Life Line Hospitals Limited has informed the Exchange that Board of Directors at its meeting held on May 10, 2024, recommended Final				
10-May-24	Jupiter Life Line Hospitals Limited has informed the Exchange regarding 'addition of 75 beds in existing Indore Hospital and 22 beds in existing				
10-May-24	Jupiter Life Line Hospitals Limited has informed the Exchange about change in Management - Appointment of Secretarial Auditor				
10-May-24	Jupiter Life Line Hospitals Limited has informed the Exchange about change in Management - Appointment of Cost Auditor				
10-May-24	Jupiter Life Line Hospitals Limited has informed the Exchange regarding Change in Director(s) of the company.				
10-May-24	Jupiter Life Line Hospitals Limited has informed the Exchange regarding Change in Director(s) of the company.				
10-May-24	Jupiter Life Line Hospitals Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32				
10-May-24	Pursuant to Regulation 32(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and 41(4) of SEBI (Issue of Capital and				
10-May-24	Jupiter Life Line Hospitals Limited has informed the Exchange about Investor Presentation				
10-May-24	JUPITER LIFE LINE HOSPITALS LIMITED has informed the Exchange regarding Outcome of Board Meeting held on 10-May-2024 for Dividend				
10-May-24	JUPITER LIFE LINE HOSPITALS LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance				
12-May-24	Jupiter Life Line Hospitals Limited has informed the Exchange about Copy of Newspaper Publication of Financial Results for quarter and year				
13-May-24	Jupiter Life Line Hospitals Limited has informed the Exchange about Link of Recording				
17-May-24	Jupiter Life Line Hospitals Limited has informed the Exchange about Transcript of the Q4 & FY24 Results Conference Call				

Note: The Company would meet Investors/ Analysts/ Participants from time to time. Please refer to the website of the Stock Exchanges for the intimation of the schedule of such meetings and related For further updates and information, please refer to the website of the Stock Exchanges i.e. www.bseindia.com and / or www.nseindia.com.

Disclaimer:

This information is gathered, inter-alia, from the Prospectus of the Issuer, as amended, and from the filings made by the Issuer with the BSE Limited ("BSE") and / or the National Stock Exchange of India Limited ("NSE" and together with the BSE, the "Stock Exchanges") from time to time, price-volume data available on the website of the Stock Exchanges, other sources as disclosed herein and information / clarifications provided by the Issuer